結腸直腸がん患者の FOLFOX6, FOLFIRI 療法における携帯型
Contents
1. A FOLFOX6 17 10 18 3 FOLFIRI 17 11 18 3 1 FOLFOX6 17 10 20 18 10 11 1 6 49 Table 2 FOLFIRI 17 11 30 18 11 29 1 8 64 Table 3 0 05 FOL FOX6 FOLFIRI2. REFERENCES 1 Kawabata Y Nakagawa A Uchikoshi H Tamiya Y Yakugaku Zasshi 129 359 364 2009 2 Japan Meteorological Agency meteorological statistics http www jma go jp jma menu report html 3 SUREFUSER A explanatory pamphlet Nipro Co C1 3000 0311SS 4 Baxter INFUSOR explanatory pamphlet Bax ter Co JLMDIF PID030 5 Hayashi H Kambe H Yosjikawa T Dai mon T Nabeta I Kimura M Yamada H Ukishima Y Inoue K Kawarasaki Y Itoh K J Jpn Hosp Pharm 45 821 824 2009 6 Tournigand C Andre T Achille E Lledo G Flesh M Mery Mignard D Quinaux E Couteau C Buyse M Ganem G Landi B Colin P Louvet C J Clin Oncol 22 229 237 2004 7 Hochster H S Hart L L Ramanathan R No 627 K Childs B H Hainsworth J D Cohn A L Wong L Fehrenbacher L Abubakr Y Saif M W Schwartzberg L Hedrick E J Clin Oncol 26 3523 3529 2008 8 Grothey A Sugrue M M Purdie D M Dong W Sargent D Hedrick E Kozloff M J Clin Oncol 26 5326 5334 2008
3. TEED D 2 3
4. LV5 SV2 invitro No 4 625 A 32 15 20 C 25 C 30C 4 exp g kgT u 4
5. 4ml 32 1st line FOLFOX6 2nd line FOLFIRI Ist line FOL FIRI 2nd line FOLFIRI6 overall survival OS 20 9 OS 79 2 3
6. DIE 46 A
7. T FOLFIRI SFU 46 210m 5FU 60 ml 3000 mg 43 64 E 150 ml In Io y 2086 8x 6 7614 andrade plot S FU andrade plot 5 GD 1 305K andrade plot physiological 1 298K saline solution j 0 00827 0 00328 0 00329 0 00330 0 00331 0 00332 0 003 0 00335 0 00336 1 T 00334 y 1847 1x 6 1954 0 3 Fig 3 Andrade Plot 5 FU 5 GI physiological saline solution 626 Vol 130 2010 SFU 60 210 28 6 5FU 3FU 28 6
8. SFU X28 6 100 0 5 1 286 15 C 1 139 20 C 1 012 25 C 0 903 30 C SFU NT B Table 5 A 5 ml h 32 32C TOLFOX 200 ml FOLFIRI 210 ml 10 3 32
9. FOLFOX6 SFU 5 en SFU 0 012 p 0 9 ED MEAO AMM E BAN am p lt 0 05 5 0 67 p lt SN 5 BEE 0 89 p lt 0 05 10 1 11 4 0 FOLFIRI SFU 0 16 p 0 20 Table 2 Total Volume and Duration of Infusion FOLFOX6 November to April May to October Total Volume Duration of Total Volume Duration of ml Infusion h ml Infusion h 180 38 200 42 180 40 200 43 180 42 200 43 180 46 200 44 200 41 200 45 200 42 200 46 200 46 200 47 200 47 210 42 200 47 210 42 200 49 210 42 205 47 210 43 205 49 210 44 205 49 210 44 205 50 210 44 210 43 210 44 210 44 210 44 220 43 210 45 220 48 210 47 220 48 210 47 230 52 210 48 250 57 210 49 250 63 220 45
10. z3 A 32 C 624 Vol 130 2010 AdjR2 0 561 y 0 234x 1 626 A actual measurement Nov to Apr actual measurement May to Oct regression line Nov to Apr regression line May to Oct O y 0 234x 3 643 A 45 A A 40 A A 35 30 170 180 190 200 210 220 240 250 260 Total Volume ml Fig 1 Correlation between Duration of Continuous Intravenous Injection by SUREFUSER A and Total Volume Nov to Apr May to Oct of FOLFOX6 actual measurement Nov to Apr Adj R2 0 694 y 0 274x 12 827 X actual measurement May to Oct regression line Nov to Apr regression line May to Oct y 0 274x 15 864 Total Volume ml 170 180 190 200 210 220 230 250 260 Fig 2 Correlation between Duration of Continuous Intravenous Injection by SUREFUSER A and Total Volume Nov to Apr May to Oct of FOLFIRI
11. 5 X30 100 0 SFU 60 ml 5 7 F YWA 140 ml 1 358 15 C 1 211 20 C 1 084 25 C 0 9737 30 0 934 SEU 60ml 5 7 FYH 140 ml 32 O nd P P 128 ul O z HAR d B PiP DT 15 C 32 0 934 1 358 0 688 32
12. e 7 Im 1 7 5FU 1 084 32 C 1 273 25 C In 6 7614 2086 8 7 Fig 3 5 0 87 32 C 1 003 25 C 0 776 32 C 0 908 25 C In 6 1954 1847 1 T In u 6 9412 2039 7 T FOLFOX6 3FU 46 200 ml T 5FU 60ml 3000 mg 27 49 5 140 ml 3FU 60 200 30 0 5FU SFU 30 0 5 SFU
13. 220 47 220 48 220 49 220 52 230 55 0 75 p lt 0 05 0 62 p lt 0 05 0 80 p lt 0 05 FOLFOX6 2 1 2 10 11 4 Excel X Statcel2 No 4 623 Table 3 Total Volume and Duration of Infusion FOLFIRI November to April May to October Total Volume Duration of Total Volume Duration of ml Infusion h ml Infusion h 180 34 200 40 250 62 200 4
14. 0 180 37 200 41 200 41 200 41 185 42 210 40 184 41 210 40 210 42 210 40 184 35 210 40 200 45 210 40 220 49 210 40 185 41 210 41 210 45 210 41 215 44 210 42 210 44 210 42 200 41 210 42 190 39 210 42 200 43 210 43 215 45 210 43 220 48 210 43 190 38 210 44 200 40 210 45 200 45 220 40 200 44 220 43 220 47 220 44 215 50 220 44 220 47 220 44 200 39 220 45 200 42 220 45 220 46 220 45 200 43 220 45 200 41 215 44 210 40 210 42 Table 4 5 10 11 4 FOLFOX6 FOLFIRI Figure 1 FOLFOX6 11 4 5 10 2 017 FOLFIRI Table 4 Multiple Regression Analysis Result of FOLFOX6 and FOLFIRI Partial regres sion coefficient svale FOLFOX6 Intercept 1 626 0 795 Total Volume ml FOLFOX 0 234 0 001 Temp May to Oct Nov to Apr 2 017 0 022 FOLFIRI Intercept 12 827 0 008 Total Volume ml FOLFOX 0 274 1 lt 0 001 Temp May to Oct Nov to Apr 3 037 lt 0 001 D
15. 00 mg m 2 h di DEN 200 mg m 2 h d1 5 FU 400 mg m bolus d1 46 46 FOLFOX6 BR 5 FU 2400 3000 mg m 46 h by SUREFUSER A d1 2 All agents dissolved in 5 Gl FOLFIRI every 2 3 weeks 2 CPT 11 80 120 mg m 90 m di de a KR En EZ 200m Re od lt 2 EN 400 mg m bolus d1 5 FU 2400 3000 mg m 46 h by SUREFUSER A d1 2 e mail mwoodmo yahoo co jp All agents dissolved in physiological saline solution 622 Vol 130 2010 46 ES 10 3
16. YAKUGAKU ZASSHI 130 4 621 627 2010 2010 The Pharmaceutical Society of Japan 621 Articles FOLFOX6 FOLFIRI A 2 The Optimal Volume of Medicinal Solution in the Portable Disposable Infusion Pump SUREFUSER A for FOLFOX6 FOLFIRI Therapy of Colorectal Cancer Patients 2nd Report Influence of Temperature on Outflow Speed of the Medicinal Solution Yoshinori KAWABATA and Akiko NAKAGAWA aDepartment of Pharmacy Niigata Cancer Center Hospital 2 15 3 Kawagishi cho Chuo ku Niigata 951 8133 Japan and Department of Pharmacy Niigata Prefectural Yoshida Hospital 32 14 Yoshidadaibo cho Tsubame Niigata 959 0242 Japan Received August 26 2009 Accepted November 22 2009 Published online December 8 2009 We formerly reported the most suitable volumes of medicinal solution for continuous SFU infusion over 46 hours in the FOLFOX6 and FOLFIRI regimens respectively by analyzing the relation of the total volume of the medicinal solu tion in a portable disposable infusion pump SUREFUSER A and the duration of infusion using a regression analysis A total infusion time of about 48 hours was obtained As the ambien
17. t temperature increased however we noticed that the continuous SFU infusion finished earlier than anticipated Using an additional analysis we found that not only the medicinal solution s original coefficient of viscosity but also the ambient temperature influenced the duration of infu sion Here we report that the speed of continuous SFU infusion increases as the coefficient of viscosity decreases in response to increases in ambient temperature Thus the composition of medicinal solutions and the ambient tempera ture must be considered to ensure a correct duration of continuous infusion Key words coefficient of viscosity temperature portable disposable infusion pump Folinic acid 5 fluorouracil and Oxaliplation 6 FOLFOX6 Folinic acid 5 Huorouracil and Irinotecan FOLFIRI m 10ml FOLFIRI zul 210 ml 46 10 ml FOLFOX6 FOLFIRI Table 1 Table 1 FOLFOX6 and FOLFIRI Regimens A SFS 5 25 32 C FOLFOX6 every 2 3 weeks 5 ml h L OHP 1
18. ummy Variable 1 May to Oct 0 Nov to Apr Table 5 Optimal Volume of Medicinal Solution in the Porta ble Disposable Infusion Pump SUREFUSER A for FOL FOX6 and FOLFIRI FOLFOX6 FOLFIRI 5 FU resolved in 5S FU resolved 5 G in physiological saline solution November to April 204 ml n 22 215 ml n 34 212 ml n 27 226 ml n 30 222 ml n 64 May to October Entire Year 208 ml n 49 Fig 2 5 10 11 4 46 Table 5 FOLFIRI 5 10 200 220 ml 226 ml 180 250 ml 11 4 5 10 Table 5
Download Pdf Manuals
Related Search